| HOME >> BIOLOGY >> TECHNOLOGY |
------------ ------------ ------------ ------------
$ $ $ $
Cash provided by
(used in)
Operating activities
Net loss for the
period (6,414,856) (3,225,371) (11,431,911) (6,453,782)
Add items not
affecting cash:
Amortization 580,733 241,887 1,074,567 469,945
Loss on sale of
property and
equipment - 1,483 - 1,483
Stock-based
compensation 175,947 186,654 355,850 365,704
Unrealized foreign
exchange loss (gain) 4,991 (128,534) 49,002 (149,544)
Non-cash interest
expense 18,288 - 37,068 -
------------ ------------ ------------ ------------
(5,634,897) (2,923,881) (9,915,424) (5,766,194)
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
Change in non-cash
working capital and
other balances
related to
operations 88,886 (686,470) 298,802 795,297
------------ ------------ ------------ ------------
Cash used in operating
activities (5,546,011) (3,610,351) (9,616,622) (4,970,897)
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
Financing activities
Issuance of capital
stock - - - 15,904,488
Share issue costs - (168,939) (57,884) (1,525,478)
Issuance of
convertible
'/>"/>
| SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved |